Clinical Trials Logo

Filter by:
NCT ID: NCT05849272 Not yet recruiting - Somatic Symptom Clinical Trials

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of somatic symptoms in depression, to provide evidence-based basis for clinical rational drug use.

NCT ID: NCT05849246 Not yet recruiting - Clinical trials for Non-squamous Non-small-cell Lung Cancer

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

Primary objective: ·To assess the antitumor activity of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population. Secondary objectives: To assess the safety and tolerability of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population. To assess the pharmacokinetic (PK) characteristic of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population.

NCT ID: NCT05848999 Recruiting - Clinical trials for Mesothelin-positive Advanced Malignant Solid Tumors

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Start date: April 27, 2023
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant solid tumors.

NCT ID: NCT05848934 Not yet recruiting - Clinical trials for Coronary Heart Disease

Research on the Relationship Between Cognitive Function Changes and Cerebrovascular Health in Patients With Coronary Heart Disease

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by combining serum markers and patient cardiovascular health evaluation indicators.

NCT ID: NCT05848921 Not yet recruiting - Clinical trials for Carotid Artery Stenosis

Evaluation of Brain Health and Surgical Efficacy in Patients With Carotid Artery Stenosis

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to explore the relationship between the recovery of cerebrovascular morphology and cognitive function before and after surgical treatment in patients with carotid artery stenosis and their preoperative cardiac health status. And combined with preoperative cognitive status, serum markers, and cardiovascular health evaluation indicators, evaluate and predict the possibility of postoperative neurodegenerative diseases and the level of cerebrovascular health in patients.

NCT ID: NCT05848648 Recruiting - Ovarian Cancer Clinical Trials

PPK Study Based on Quantitative Pharmacology in Patients With Pamipril

Start date: May 1, 2023
Phase:
Study type: Observational

This is a non-intervention, prospective, one-arm, observational real-world clinical trial. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study was to establish a population pharmacokinetic model of Pamiparib and to explore the correlation between its pharmacokinetic parameters and adverse reactions.

NCT ID: NCT05848466 Recruiting - Clinical trials for Advanced or Metastatic Solid Tumors

Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

The goal of this interventional study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BAT8010 for injection in patients with advanced or metastatic solid tumors, explore the maximum tolerable dose. Participants will be given one of below dose once every three weeks: 0.8mg/kg, 1.2mg/kg, 2.4mg/kg, 3.6mg/kg, 4.8mg/kg, 6.0mg/kg, 7.2mg/kg, 8.4mg/kg. The dose escalation follow adopt accelerated titration and "3+3" dose increasing rule.

NCT ID: NCT05848310 Recruiting - Prognosis Clinical Trials

Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

Start date: October 15, 2023
Phase:
Study type: Observational

To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.

NCT ID: NCT05848167 Recruiting - Clinical trials for Osteoporotic Fractures

Senile Osteoporotic Fractures Cohort Study(SOFCS)

Start date: July 15, 2021
Phase:
Study type: Observational

Osteoporotic fracture is one of the main causes of disability and death in elderly patients. Specific disease cohort study is an important basis for accurate prevention and treatment of senile osteoporotic fractures. Investigators plan to collect and manage the baseline and clinical information of more than 2000 elderly patients with osteoporotic fractures after surgery through the platform of special disease collaborative prevention and treatment system and medical record database of Suzhou Municipal Hospital in two years, and carry out short-term and long-term follow-up observation.

NCT ID: NCT05848154 Not yet recruiting - Clinical trials for Patients With Non-metastatic Pancreatic Cancer

Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer

Start date: June 1, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the value of ctDNA detection in the assessment of response rate to neoadjuvant chemotherapy in pancreatic cancer and to explore the correlation between ctDNA clearance and prognosis at different time points. Meanwhile, whole exome sequencing (WES) and RNA Sequencing (RNA-seq) of samples of responders and non-responders to neoadjuvant chemotherapy before and after treatment are performed to explore the mechanisms of drug resistance and provide guidance for clinical decision making.